Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Plans $0.94 Quarterly Dividend

Key Points

• Regeneron declared a quarterly dividend of $0.94 per share (annualized $3.76) with an ex-dividend date of May 20 and payable June 4, implying a ~0.5% yield and a payout ratio well covered by earnings (~9.6%).
• Q1 beat: Regeneron reported non‑GAAP EPS of $9.47 and revenue of $3.61B (up 19% YoY), topping estimates.
• Despite the beat the stock slid about 6.2% intraday on weaker-than-expected total EYLEA U.S. sales and rising competitive risks in the retina market, though management authorized up to a $3 billion buyback.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) declared a quarterly dividend on Wednesday, April 29th. Stockholders of record on Wednesday, May 20th will be given a dividend of 0.94 per share by the biopharmaceutical company on Thursday, June 4th. This represents a c) annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th.

Regeneron Pharmaceuticals has a dividend payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Regeneron Pharmaceuticals to earn $42.14 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 8.9%.

Regeneron Pharmaceuticals Stock Down 6.2%

Shares of REGN stock traded down $45.41 during trading hours on Wednesday, hitting $686.36. 1,831,580 shares of the company's stock traded hands, compared to its average volume of 741,458. The stock's fifty day simple moving average is $760.43 and its two-hundred day simple moving average is $735.71. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The stock has a market cap of $72.56 billion, a price-to-earnings ratio of 16.51, a PEG ratio of 1.71 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.10 by $0.37. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.45 billion. During the same period last year, the business earned $8.22 earnings per share. The business's revenue was up 19.0% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals will post 35.98 EPS for the current year.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 beat on both EPS and revenue: Regeneron reported non‑GAAP EPS of $9.47 and revenue of ~$3.6B, topping estimates and showing 19% revenue growth — a strong near‑term financial print. Regeneron beats quarterly results estimates on strong Dupixent demand (Reuters)
• Positive Sentiment: Dupixent and EYLEA HD momentum: Dupixent demand remains a key growth driver (Sanofi‑reported Dupixent sales +33%); EYLEA HD U.S. adoption rose sharply (EYLEA HD U.S. net sales +52%), supporting medium‑term growth prospects. Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Zacks)
• Positive Sentiment: $3B buyback announced: Management authorized up to $3 billion in share repurchases, which supports EPS and signals management confidence. Regeneron shares slide despite Q1 beat (ProactiveInvestors)
• Neutral Sentiment: Pipeline milestones could be value drivers but are not immediate: Progress in the C5 complement program (PNH enrollment complete) and positive Phase III data for cemdisiran in myasthenia gravis set up potential multi‑indication launches as early as Q4 2026 — longer‑term upside if approvals materialize. Regeneron’s C5 Milestones And Autoimmune Bets Shape Future Valuation (Yahoo)
• Neutral Sentiment: Full earnings call details and management commentary available for color on margins, IPR&D impacts and product cadence — useful for modeling but not a single catalyst. Regeneron Q1 2026 Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: EYLEA U.S. sales disappointed vs. Street expectations: Despite HD uptake, total EYLEA U.S. net sales declined ~10% and reported U.S. high‑dose sales missed expectations, fueling the intraday selloff. Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug (Yahoo)
• Negative Sentiment: Rising competition and upcoming biosimilars/new entrants: Analysts flag intensified competition in the retina market and several competitors with data or launches coming later this year, which could pressure EYLEA revenue and valuation going forward. Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. (Yahoo)

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.